+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
MALE
ID07103018

Dose Escalation Study of KTX-2001 Alone and With Darolutamide for Metastatic Castration-Resistant Prostate Cancer

Led by K36 Therapeutics, Inc. · Updated on 2026-10-20

144

Participants Needed

13

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating KTX-2001, alone and combined with darolutamide, in men with metastatic castration-resistant prostate cancer mCRPC. This Phase 1, open-label study aims to assess the safety, dosage limits, how the drugs behave in the body, and preliminary effectiveness in treating mCRPC. The trial also seeks to establish recommended doses for future studies. Participants receive escalating doses of KTX-2001 by mouth either alone or together with oral darolutamide at a total daily dose of 1200 mg. The study has two parts Part A focuses on KTX-2001 alone, and Part B studies the combination with darolutamide. Dose escalation continues to determine safe and tolerable levels. During the study, participants undergo baseline and on-treatment biopsies when feasible, imaging scans to confirm metastatic disease, and regular safety monitoring. Researchers measure dose-limiting toxicities within 21 days to find the maximum tolerated dose, along with pharmacokinetics, safety events over up to 3 years, and recommended dosing. Participants are closely observed throughout treatment and follow-up periods until study completion.

CONDITIONS

Brief Title

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Research Team

K

K36 Clinical Operations

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here